Literature DB >> 1867191

Neuroanatomy in fragile X females: the posterior fossa.

A L Reiss1, L Freund, J E Tseng, P K Joshi.   

Abstract

The relative homogeneity of the neuropsychiatric phenotype in individuals with fragile (fra) X syndrome suggests that there are consistent central nervous system (CNS) abnormalities underlying the observed cognitive and behavioral abnormalities. In this study, the neuroanatomy of the posterior fossa and other selected CNS regions in 12 young fra X females were compared with those of a group of 12 age-, sex-, and IQ-matched females without evidence of the fra X syndrome. Fra X females were shown to have decreased size of the posterior cerebellar vermis and increased size of the fourth ventricle, findings that are identical to those previously reported for fra X males. When compared with fra X male and nonfra X control groups, the distribution of the posterior-vermis and fourth-ventricle variables for the fra X female group was intermediate. These results support the hypothesis that the fra X genetic abnormality leads to hypoplasia of the posterior cerebellar vermis, a neuroanatomical variation of potential importance to both developmental and neuropsychiatric syndromes.

Entities:  

Mesh:

Year:  1991        PMID: 1867191      PMCID: PMC1683304     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  22 in total

1.  Parental inheritance and psychological disability in fragile X females.

Authors:  A L Reiss; L Freund; S Vinogradov; R Hagerman; A Cronister
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

2.  Hypoplasia of cerebellar vermal lobules VI and VII in autism.

Authors:  E Courchesne; R Yeung-Courchesne; G A Press; J R Hesselink; T L Jernigan
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

3.  Social gaze, social avoidance, and repetitive behavior in fragile X males: a controlled study.

Authors:  I L Cohen; G S Fisch; V Sudhalter; E G Wolf-Schein; D Hanson; R Hagerman; E C Jenkins; W T Brown
Journal:  Am J Ment Retard       Date:  1988-03

4.  The cerebellum in sagittal plane--anatomic-MR correlation: 1. The vermis.

Authors:  E Courchesne; G A Press; J Murakami; D Berthoty; M Grafe; C A Wiley; J R Hesselink
Journal:  AJR Am J Roentgenol       Date:  1989-10       Impact factor: 3.959

5.  Cerebellar vermis dysplasia: diagnostic problems by CT.

Authors:  P Curatolo; E Cotroneo
Journal:  Neuropediatrics       Date:  1982-02       Impact factor: 1.947

6.  Cognitive profiles associated with the fra(X) syndrome in males and females.

Authors:  L S Freund; A L Reiss
Journal:  Am J Med Genet       Date:  1991-03-15

7.  Reduced cerebellar hemisphere size and its relationship to vermal hypoplasia in autism.

Authors:  J W Murakami; E Courchesne; G A Press; R Yeung-Courchesne; J R Hesselink
Journal:  Arch Neurol       Date:  1989-06

8.  Cognitive profiles of boys with the fragile X syndrome.

Authors:  M B Kemper; R J Hagerman; D Altshul-Stark
Journal:  Am J Med Genet       Date:  1988 May-Jun

Review 9.  Fragile X and autism: a multicenter survey.

Authors:  W T Brown; E C Jenkins; I L Cohen; G S Fisch; E G Wolf-Schein; A Gross; L Waterhouse; D Fein; A Mason-Brothers; E Ritvo
Journal:  Am J Med Genet       Date:  1986 Jan-Feb

10.  Autism in fragile X females.

Authors:  R J Hagerman; A E Chudley; J H Knoll; A W Jackson; M Kemper; R Ahmad
Journal:  Am J Med Genet       Date:  1986 Jan-Feb
View more
  21 in total

Review 1.  Fragile X: leading the way for targeted treatments in autism.

Authors:  Lulu W Wang; Elizabeth Berry-Kravis; Randi J Hagerman
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 2.  Insights into brain development from neurogenetic syndromes: evidence from fragile X syndrome, Williams syndrome, Turner syndrome and velocardiofacial syndrome.

Authors:  E Walter; P K Mazaika; A L Reiss
Journal:  Neuroscience       Date:  2009-04-17       Impact factor: 3.590

3.  Neuroanatomical abnormalities in fragile X syndrome during the adolescent and young adult years.

Authors:  Gisela M Sandoval; Sehoon Shim; David S Hong; Amy S Garrett; Eve-Marie Quintin; Matthew J Marzelli; Swetapadma Patnaik; Amy A Lightbody; Allan L Reiss
Journal:  J Psychiatr Res       Date:  2018-10-25       Impact factor: 4.791

Review 4.  Neural phenotypes of common and rare genetic variants.

Authors:  Carrie E Bearden; David C Glahn; Agatha D Lee; Ming-Chang Chiang; Theo G M van Erp; Tyrone D Cannon; Allan L Reiss; Arthur W Toga; Paul M Thompson
Journal:  Biol Psychol       Date:  2008-02-23       Impact factor: 3.251

5.  Fragile-X: neuropsychological test performance, CGG triplet repeat lengths, and hippocampal volumes.

Authors:  P Jäkälä; T Hänninen; M Ryynänen; M Laakso; K Partanen; A Mannermaa; H Soininen
Journal:  J Clin Invest       Date:  1997-07-15       Impact factor: 14.808

Review 6.  Comprehensive neurocognitive endophenotyping strategies for mouse models of genetic disorders.

Authors:  Michael R Hunsaker
Journal:  Prog Neurobiol       Date:  2012-01-13       Impact factor: 11.685

7.  Eye movements reveal impaired inhibitory control in adult male fragile X premutation carriers asymptomatic for FXTAS.

Authors:  Ling M Wong; Naomi J Goodrich-Hunsaker; Yingratana McLennan; Flora Tassone; Melody Zhang; Susan M Rivera; Tony J Simon
Journal:  Neuropsychology       Date:  2014-04-28       Impact factor: 3.295

Review 8.  Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies.

Authors:  Amy A Lightbody; Allan L Reiss
Journal:  Dev Disabil Res Rev       Date:  2009

9.  The role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndrome.

Authors:  Samantha Portis; Brian Giunta; Demian Obregon; Jun Tan
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-09-20

10.  Genotype-phenotype relationships in fragile X syndrome: a family study.

Authors:  D Z Loesch; R Huggins; D A Hay; A K Gedeon; J C Mulley; G R Sutherland
Journal:  Am J Hum Genet       Date:  1993-11       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.